Does sacral nerve stimulation improve global pelvic function in women?

Jadav, A. M.; Wadhawan, Himanshu; Jones, Georgina; Wheldon, L; Radley, Stephen; Brown, S. R.

doi:10.1111/codi.12181

Cited by 34 publications

(13 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neuromodulation certainly has a role as a treatment of dual incontinence (such as urinary and faecal incontinence) 172 . However, given emerging reports of efficacy in patients with additional bowel conditions, such as constipation 173 , functional anal pain 174 , IBS 175 , and pelvic conditions 175 such as IC/BPS 176–178 , sacral neuromodulation might have a role in individuals with multiple pelvic comorbidities. Additional research into how patients with comorbidities such as those described above respond to OAB therapies is needed 163 .…”

Section: Implications For Oab Treatmentmentioning

confidence: 99%

Does central sensitization help explain idiopathic overactive bladder?

et al. 2016

View full text Add to dashboard Cite

The pathophysiological mechanisms underlying overactive bladder syndrome (OAB) can include dysfunction of sensory pathways of the peripheral and central nervous systems, resulting in bladder hypersensitivity. Central sensitization describes an induced state of spinal hypersensitivity that is associated with a variety of chronic pain disorders that share many attributes with OAB, albeit without the presence of pain. As such, the concept of central sensitization might be relevant to understanding the mechanisms and clinical manifestations of OAB syndrome. An understanding of the pathophysiology and clinical manifestations of central sensitization, and the evidence that supports a role of central sensitization in OAB, including the potential implications of mechanisms of central sensitization for the treatment of patients with OAB could provide a novel approach to the treatment of patients with this disease. Such an approach would be especially relevant to those patients with central sensitization-related comorbidities, and has the potential to improve the outcomes of these patients in particular.

show abstract

Section: Implications For Oab Treatmentmentioning

confidence: 99%

Does central sensitization help explain idiopathic overactive bladder?

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The objective assessment of sexual function in a treatment approved for NLUTS is a new strategy of evaluation. Although definitive SNM is not yet indicated for sexual dysfunction, an objective evaluation approach regarding sexual function should be recommended for all neurological patients . The mechanism of SNM on sexual function is unknown, but potential direct mechanisms are possible.…”

Section: Discussionmentioning

confidence: 99%

Management of sexual dysfunction due to central nervous system disorders: a systematic review

et al. 2015

View full text Add to dashboard Cite

Objective To systematically review the management of sexual dysfunction due to central nervous system (CNS) disorders. Patients and Methods The review was done according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) statement. Studies were identified independently by two reviewers using electronic searches of MEDLINE and OVID (from January 2004 to August 2014) and hand searches of reference lists and review articles. Results In patients with CNS disorders, neuro‐urological assessment is recommended for both genders before starting any treatment for sexual dysfunction. For men, blood sexual hormones evaluation is the main investigation performed before phosphodiesterase type 5 inhibitors (PDE5Is) treatment, whereas there is no consensus on routine laboratory tests for women. PDE5Is are the first‐line medical treatment for men, with the most robust data derived from patients with spinal cord injury assessed by validated questionnaires, mainly the International Index of Erectile Function‐15. There is no effective medical treatment for sexual dysfunction in women. Sacral neuromodulation for lower urinary tract dysfunction may improve sexual dysfunction in both genders. Conclusions Although sexual dysfunction is a major burden for patients with CNS disorders, high‐evidence level studies are rare and only available for PDE5Is treating erectile dysfunction. Well‐designed prospective studies are urgently needed for both genders.

show abstract

“…A detailed quality‐of‐life assessment was undertaken for each patient using the ePAQ tool . Optimization was defined as diary evidence of a similar response to that obtained with PNE, combined with satisfactory symptom control and no need for device reprogramming.…”

Section: Methodsmentioning

confidence: 99%

“…Four patient groups were identified: group 1: optimized after the initial 2-week review; group 2: optimized after subsequent reviews; group 3: never optimized; group 4: optimized, but subsequently deteriorated. A detailed quality-of-life assessment was undertaken for each patient using the ePAQ tool [12]. Optimization was defined as diary evidence of a similar response to that obtained with PNE, combined with satisfactory symptom control and no need for device reprogramming.…”

Section: Methodsmentioning

confidence: 99%